C’Dots, silica-encased nanoparticles developed in the lab of engineering professor Ulrich Wiesner, have just begun their first therapeutic human clinical trial. They’re being further developed by Elucida Oncology Inc., a company co-founded by Wiesner.
New York State Impact
“The new financial products emerging in the blockchain ecosystem carry tremendous promise along many dimensions. This promise is especially marked smart contracts, which enable the creation of financial instruments with unprecedented transparency, mechanization and auditability. At the same time, carefully considered regulation is a necessity, given the myriad risks engendered by blockchain-based financial technologies. Apart from the risk of financial instability, the risks of exploitative arbitrage, pyramid schemes and environmental damage are often underappreciated."